Preparation for preventing transport stress in cattle youngsters

FIELD: animal science.

SUBSTANCE: the suggested biopreparation named "Lactobifadol" should be applied 1 mo before the impact of the mentioned stress factor at the dosage of 100-200 mg/kg body weight, daily. Application of "Lactobifadol" enables to normalize physiological body state and decrease the losses of meat production.

EFFECT: higher efficiency of prophylaxis.

1 ex, 2 tbl

 

The invention relates to agricultural production, in particular livestock, and can be used to reduce losses of meat products at the technological stresses, such as pre-training of young cattle.

It is known that when technological stresses arising during rearing, fattening and implementation of the young, lose up to 30% of meat products (1). Therefore, in practice, to reduce stress on the animals use a variety of pharmacological tools-tranquilizers, thyreostatic medicinal drugs, antioxidants, antibiotics, organosilicon and others (2,3). However, in most cases they have a short action, scarce and expensive.

Known use as a means for the prevention of transport stress in animals biological product of carmagazine (2).

It is effective only when the fodder stress and therefore has not found wide use as an anti-stress drug.

The essence of the invention lies in the fact that for the first time as a means to prevent transport stress in young cattle is applied biological product "Lactometer" one month prior to exposure to the stress factor at a dose of 100-200 mg/kg body weight per day.

Lactometer is a drug for veterinary use, made from live bacteria species B.adolescentis and L.acidophilum in the body synthesizes vitamin b, Biotin, vitamins K, C and other, currently used exclusively for the prevention and treatment of gastrointestinal diseases (4). As an anti-stress drug it is used for the first time.

Specific example

JSC "Key" of the Orenburg region were selected 35 bulls Simmental breed, of which the principle analogues formed seven groups - control and six experienced. The difference lay in the fact that in contrast to control animals (I, II, III, IV, V experimental groups one month prior to slaughter was additionally fed probiotic of lactometer in the amount of respectively 50, 100, 150, 200, 250 mg/kg body weight, and VI - biological chromogranin dose of 12000 UNITS per head per day. Conditions, the General level of feeding and the structure of the experimental diet of young animals of all groups were identical. The animals were housed on feedlots. The meat is transported in specially equipped vehicles. The transportation distance of 110 km

Feeding animals laccopetalum contributed to the reduction of losses in live weight during transportation average 32 kg or 11.9%. If in the control group they were 26.9 kg, the experimental average of 23.7 kg Indicators to reduce losses of meat products at the salvage stress with the help of a biological product of Lactoridaceae presented in table. 1.

The smallest loss of cultivated production was observed in young II, IV, and especially III groups. In particular, at last they was 22.5 kg (5,12%), while in the control and 26.9 kg (6,14%), I experienced to 24.6 (5,63%), in the II - 22,9 (to 5.21%), IV - 23,0 (5,25%), V - 24,6 (5,64%) and VI - 24,4 kg (5,57%), that is, when the feeding of the calves of the test drug at a dose of 150 mg/kg live weight for the period of transportation was more significant than the other groups.

For the pre-slaughter period 24-hour hungry excerpts loss of body weight in the control group amounted to 17.8 kg or 4,33% of baseline, whereas in the experimental average of 15.2 kg or 3,68%. And in this case, the least they were in the third experimental group was 14.7 kg (3.52 per cent).

The total loss of body weight during the period of pre-training (transportation and hungry extract) in the control group was 44.7 kg or 10,20% from removable mass and experienced - an average of 38.9 kg (8,89%). Reduction

loss of body weight when fed lactosefree dose of 50 mg/kg 4.9 kg(1,08%), 100 - 6,8 (1,57%), 150-7,5 (1,74%), 200-6,3 (1,44%), 250-4,4 (0,96%), carmagazine dose 12000 IU - 4.8 kg (1,09%).

The experimental feeding young animals lactosefree, and in the VI group carmagazine has increased carcass weight and visceral fat of animals I, II, III, IV, V and VI experimental groups respectively 5,3 (2,5%), 2,0 (0,9%), 8,3 kg(3,9%), 3,0 (1,0%), 5,3 (2,5%), 4,5 kg (2.1%), and 0.7(6.1 per cent), 0,3 (2,5%), 0,6 (5,2%), 0,2 (1,7%), 0,5 (4,3%), 0,6 kg (5.2 percent).

At slaughter the output of the control animals succumbed to the young I experienced groups 0.76%II by 0.47%, III - 0.95%, IV - 0.68%, V - 0.44% experienced and VI - 0.29%.

The bulls experienced groups, especially II and III were fewer confiscated in the processing of carcasses, indicating their best pre-training.

The results showed that stress caused by transportation, has some effect on hematological indices, characterizing the strain of the organism. Morphological and biochemical blood composition is given in table. 2.

After transporting the calves of the control group in the blood increased content of erythrocytes by 9.9%, leukocyte - 7.5%, hemoglobin - by 7.0%, total protein, 3.4%, lipids, 7.6%, sugar - by 23.7%. This reflects both the increased when levels of stress, protein, lipid and carbohydrate metabolism, and dehydration (water loss) of the body. The latter is evidenced by increased hematocrit blood on 7,87%.

The normalization of the physiological state of the animals when exposed to transport stress contributed to the feeding of the test drug. The least change in the composition of the blood of calves was observed in the third experimental group, the young of which was received in addition to the diet of 150 mg/kg body missapropriation of lactoridaceae. In this case, we can only talk about the trend towards greater hematological parameters when exposed to TRANS tailor

the stress factor as the difference between the initial level and after the transportation of animals was not statistically significant. Several similar change in the composition of blood was observed in young II and IV experimental groups, although in this case the difference before and after transportation was more visible.

The positive influence of lactoridaceae on the body of the animal compared to similar more pronounced, due to the fact that he's in the gastrointestinal tract exhibits a pronounced antagonism against pathogenic and conditionally pathogenic microbes, thereby creating a favorable environment for the development of the necessary organisms, increases enzyme activity and metabolism, synthesize b vitamins, vitamins K and C, Biotin, improving overall immune system of the organism and its resistance to stress factors.

Using lactosefree as an anti-stress drug is economically profitable. And the greatest effect is achieved when fed to animals, the drug in a dose of 150 mg/kg body weight. Additional profit in this case an average of 206 rubles per animal, while at 100 mg/kg - 170 rubles, 20 mg/kg 40 rubles during feeding cor-magazine - 154 rubles

Thus, the use of Lactoridaceae as a means to prevent transport stress in young cattle helps to normalize the physiological state of the body, loss of meat products, as evidenced by, respectively, the results of hematologic studies and the results of the control of slaughter. The highest performance is achieved when using this drug in a dose of 100-200 mg/kg body weight per day.

Sources of information taken into account in the examination

1. Fomichev P., Levantin DL pre-Slaughter stress and quality of beef. - M.: Rosselchozizdat, 1981. - 166 C.

2. Sizov F.M., Levaxin VI Correction of stress in young cattle. Orenburg, 1999. - P.129-130 (similar).

3. Lyapin O.A., Levaxin VI, Lyapina V.O. Way to prevent technological stresses in young cattle. Patent of the Russian Federation No. 2147799, 2000.

4. Subbotin V.V., Danilevskaya, NV New prebiotic // Farmer, - 1998. No. 4. - P.20.

The use of a biological product of Lactoridaceae as a means to prevent transport stress in young cattle.



 

Same patents:

FIELD: medicine.

SUBSTANCE: means comprises amber acid and/or its salts, fructose, dry extraction of Saint John's wort, magnesium ion sources, potassium ion sources as active bases and auxiliary substances, carriers and/or fillers when needed.

EFFECT: enhanced effectiveness of treatment.

4 cl, 4 tbl

FIELD: medicine.

SUBSTANCE: method involves estimating vegetative tonus using cardiointervalography approach and its medication adjustment under cardiointervalography control. The cardiointervalography examination is carried out before applying treatment, in the course of and after the treatment. Each time vegetative tonus increment is estimated on the basis of voltage index. When applying medication adjustment, nootrop group preparations are used that are selected before applying treatment with initial vegetative tonus disorder distinguished by vagotonia or sympathicotonia being taken into account. Preparation or combination of preparations or their doses and application duration is adjusted on basis of vegetative status direction changes obtained from cardiointervalography examination data. The treatment is continued until vegetative status direction change stops towards normotonia.

EFFECT: enhanced effectiveness in selecting individual treatment course.

3 cl, 3 dwg

FIELD: pharmaceutical chemistry, in particular pharmaceutical compositions.

SUBSTANCE: new spyro(2H-1-benzopyrane-2,4'-piperidine) derivatives of general formula I

and pharmaceutically acceptable salts thereof are disclosed. In formula dotted line is optional bond; Y is 1-4 substituents independently selected from hydrogen, halogen, C1-C4-alkyl, optionally substituted with one or more halogen, C1-C6-alkyloxy, optionally substituted with halogen or C3-C6-cycloalkyl, C2-C6-alkenyloxy, C2-C6-alkinyloxy, C3-C6-cycloalkyloxy, C6-C12-aryloxy, arylalkyloxy, pyridilmethoxy, SR3, NR3R4, OSO2R5, and NR3SO2R4; or two Y together may form O-(CH2)n-O or O-(CF2)n-O, wherein n is 1 or 2: or Y is condensed C5-C6-aryl group; X is 1-3 substituents independently selected from hydrogen, halogen, hydroxyl, C1-C6-alkoxy, and C1-C4-alkyl; R1 is hydrogen, C1-C4-alkyl, or C6-C12-aryl; R2, R3, and R4 are independently hydrogen or C1-C4-alkyl; R5 is C6-C12-aryl. Also disclosed are pharmaceutical compositions including said derivatives and having activity in relation to CNS.

EFFECT: new compounds with valuable pharmacological action.

9 cl, 1 tbl, 83 ex

FIELD: medicine, obstetrics.

SUBSTANCE: the present innovation deals with three types of species of medicinal plants to prevent late gestoses in pregnant women out of high-risk group: for pregnant women in case of affected dream the suggested species contains flowers of camomile and calendula, leaves of Bergenia and balm, hops collective fruits, and dogrose fruits taken at a certain ratio; for pregnant women in case of chronic urinary infection and neurocirculatory dystonia it contains flowers of camomile and calendula, mountain ash and dogrose fruits, fruits and seeds of Schizandra, leaves of Bergenia and bearberry taken at a certain quantitative ratio; for pregnant women in case of thyroid dysfunction and affected metabolism it contains flowers of camomile and Filipendula, bearberry leaves, Bupleurum grass, fennel seeds, valerian rhizome and roots, hops collective fruits, fruits of black currant taken at a certain quantitative ratio. Species of medicinal plants efficiently prevents and treats at development of both early and late gestoses in pregnant women.

EFFECT: higher efficiency of prophylaxis and therapy.

3 cl, 3 ex

FIELD: medicine.

SUBSTANCE: method involves administering typical neuroleptics according to titration scheme and tricyclic antidepressants. Neuroleptics are applied according to titration scheme in the morning and tricyclic antidepressants are introduced as intravenous drop-by-drop infusion in the evening in combination with per os application of atypic neuroleptic risperidon. After having given 12-14 intravenous infusions, strategic supporting risperidon psychopharmacotherapy in combination with tricyclic antidepressants during 4-6 months.

EFFECT: enhanced effectiveness in overcoming pharmacological resistance; accelerated schizo-affective syndrome relief.

FIELD: medicine.

SUBSTANCE: method involves administering typical tricyclic antidepressants combined with selective reverse serotonin capture inhibitors. Anxious version of subpsychotic level depressive syndrome of endogenous genesis being treated, intravenous drop-by-drop infusion of 2.-4.0 ml of 1% amitriptiline solution per 200 ml of physiologic saline is applied in 12-14 procedures combined with selective reverse serotonin capture inhibitor given per os, Zoloft is per os administered as the inhibitor at a dose of 50-100 mg. Then, supporting Zoloft therapy is applied at a dose of 100 mg during 3 months. Atypic version of depressive syndrome of subpsychotic level and endogenous genesis is treated with intravenous drop-by-drop infusion of 1.25% Melipramine solution at a dose of 2.0-4.0 ml per 200 ml of power supply source in 12-14 infusions combined with a reverse serotonin capture inhibitor. Paxyl is taken at a peroral dose of 40-60 mg as the inhibitor. Then, supporting Paxyl therapy is applied at a dose of 40-60 mg during 3 months.

EFFECT: enhanced effectiveness of treatment; reduced risk of complications; accelerated depressive syndrome relief.

FIELD: organic chemistry, biochemistry, biology.

SUBSTANCE: invention relates to a pharmaceutical composition eliciting the inhibitory effect on activity of serine protease (caspase-3) in the form of tablet, capsule or injections placed into acceptable package, to a method for its preparing and a method for treatment of diseases associated with enhanced activation of apoptosis. The composition comprises compound 2,3-dihydro-1H-benzo[g]pteridine-4-one of the general formula (1) (1)

or its salt with pharmacologically acceptable acid as an active component taken in pharmaceutically effective amount wherein X means oxygen (O) or sulfur (S) atom; R1 and R2 represent independently of one another hydrogen atom, inert substitute taken among the group including low- or non-reactive and optionally substituted radical, such as (C1-C7)-alkyl, (C2-C7)-alkenyl, (C2-C7)-alkynyl, (C1-C7)-alkoxy-group, (C7-C12)-aralkyl, (C7-C12)-heterocyclylalkyl, (C7-C12)-alkaryl, (C3-C10)-cycloalkyl, (C3-C10)-cycloalkenyl, phenyl, aryl, heterocyclyl; optionally substituted hydroxy-(C1-C5)-alkyl group; R3, R4, R5 and R6 represent independently of one another hydrogen, halogen atom, -CF3, -CN, inert substitute taking among the group including low- or non-reactive and optionally substituted radical, optionally substituted hydroxyl group, optionally substituted hydroxy-(C1-C5)-alkyl group, optionally substituted amino-group, optionally substituted amino-(C1-C7)-alkyl group, optionally substituted carboxy-(C1-C7)-alkyl group, optionally substituted (C1-C6)-alkylcarboxy-(C1-C6)-alkyl group, optionally substituted carbamoyl group, optionally substituted (C1-C6)-alkylcarbamoyl group, optionally substituted sulfamoyl group. Also, invention relates to applying compounds of the formula (1) for preparing pharmaceutical composition and experimental study (in vitro and in vivo) processes associated with apoptosis.

EFFECT: improved preparing method, valuable medicinal and biochemical properties of composition.

7 cl, 1 dwg, 2 tbl, 5 ex

FIELD: organic chemistry, biochemistry, biology.

SUBSTANCE: invention relates to a pharmaceutical composition eliciting the inhibitory effect on activity of serine protease (caspase-3) in the form of tablet, capsule or injections placed into acceptable package, to a method for its preparing and a method for treatment of diseases associated with enhanced activation of apoptosis. The composition comprises compound 2,3-dihydro-1H-benzo[g]pteridine-4-one of the general formula (1) (1)

or its salt with pharmacologically acceptable acid as an active component taken in pharmaceutically effective amount wherein X means oxygen (O) or sulfur (S) atom; R1 and R2 represent independently of one another hydrogen atom, inert substitute taken among the group including low- or non-reactive and optionally substituted radical, such as (C1-C7)-alkyl, (C2-C7)-alkenyl, (C2-C7)-alkynyl, (C1-C7)-alkoxy-group, (C7-C12)-aralkyl, (C7-C12)-heterocyclylalkyl, (C7-C12)-alkaryl, (C3-C10)-cycloalkyl, (C3-C10)-cycloalkenyl, phenyl, aryl, heterocyclyl; optionally substituted hydroxy-(C1-C5)-alkyl group; R3, R4, R5 and R6 represent independently of one another hydrogen, halogen atom, -CF3, -CN, inert substitute taking among the group including low- or non-reactive and optionally substituted radical, optionally substituted hydroxyl group, optionally substituted hydroxy-(C1-C5)-alkyl group, optionally substituted amino-group, optionally substituted amino-(C1-C7)-alkyl group, optionally substituted carboxy-(C1-C7)-alkyl group, optionally substituted (C1-C6)-alkylcarboxy-(C1-C6)-alkyl group, optionally substituted carbamoyl group, optionally substituted (C1-C6)-alkylcarbamoyl group, optionally substituted sulfamoyl group. Also, invention relates to applying compounds of the formula (1) for preparing pharmaceutical composition and experimental study (in vitro and in vivo) processes associated with apoptosis.

EFFECT: improved preparing method, valuable medicinal and biochemical properties of composition.

7 cl, 1 dwg, 2 tbl, 5 ex

FIELD: organic chemistry, biochemistry, biology.

SUBSTANCE: invention relates to a pharmaceutical composition eliciting the inhibitory effect on activity of serine protease (caspase-3) in the form of tablet, capsule or injections placed into acceptable package, to a method for its preparing and a method for treatment of diseases associated with enhanced activation of apoptosis. The composition comprises compound 2,3-dihydro-1H-benzo[g]pteridine-4-one of the general formula (1) (1)

or its salt with pharmacologically acceptable acid as an active component taken in pharmaceutically effective amount wherein X means oxygen (O) or sulfur (S) atom; R1 and R2 represent independently of one another hydrogen atom, inert substitute taken among the group including low- or non-reactive and optionally substituted radical, such as (C1-C7)-alkyl, (C2-C7)-alkenyl, (C2-C7)-alkynyl, (C1-C7)-alkoxy-group, (C7-C12)-aralkyl, (C7-C12)-heterocyclylalkyl, (C7-C12)-alkaryl, (C3-C10)-cycloalkyl, (C3-C10)-cycloalkenyl, phenyl, aryl, heterocyclyl; optionally substituted hydroxy-(C1-C5)-alkyl group; R3, R4, R5 and R6 represent independently of one another hydrogen, halogen atom, -CF3, -CN, inert substitute taking among the group including low- or non-reactive and optionally substituted radical, optionally substituted hydroxyl group, optionally substituted hydroxy-(C1-C5)-alkyl group, optionally substituted amino-group, optionally substituted amino-(C1-C7)-alkyl group, optionally substituted carboxy-(C1-C7)-alkyl group, optionally substituted (C1-C6)-alkylcarboxy-(C1-C6)-alkyl group, optionally substituted carbamoyl group, optionally substituted (C1-C6)-alkylcarbamoyl group, optionally substituted sulfamoyl group. Also, invention relates to applying compounds of the formula (1) for preparing pharmaceutical composition and experimental study (in vitro and in vivo) processes associated with apoptosis.

EFFECT: improved preparing method, valuable medicinal and biochemical properties of composition.

7 cl, 1 dwg, 2 tbl, 5 ex

FIELD: pharmacology.

SUBSTANCE: one should apply glycosaminoglycanes at average molecular weight being 2400 D to prepare pharmaceutical composition for treating senile feeble-mindedness and neurological cerebral lesions induced due to sudden attack or trauma. The innovation suggested increases the number of medicinal preparations of necessary indication.

EFFECT: higher efficiency of application.

7 cl, 2 dwg, 8 tbl

FIELD: biotechnology, veterinary science.

SUBSTANCE: he present innovation deals with manufacturing biopreparations for oral immunization in animals. One should grow vaccinia rabic virus, TC-80 strain in a certain passage cell culture to mix it with protective components (peptone, lactose, pectin). Mixing should be carried out at 14 : 5 : 1 ratio (viral suspension : stabilizing medium, consisting of 40% peptone solution with 8% lactose solution : 4% pectin solution, correspondingly), a semifinished product obtained after mixing should be applied onto a bait (a porous briquette) to be frozen and freeze dried for 24-30 h. The method includes decreased number of stages for manufacturing necessary vaccine being more efficient and economical. The vaccine keeps immunogenic properties for 5 d, not less at environmental temperature being up to 20 C and during storage period for 6 mo at 6-8 C.

EFFECT: higher efficiency of manufacturing.

2 ex, 1 tbl

FIELD: biotechnology, veterinary science.

SUBSTANCE: he present innovation deals with manufacturing biopreparations for oral immunization in animals. One should grow vaccinia rabic virus, TC-80 strain in a certain passage cell culture to mix it with protective components (peptone, lactose, pectin). Mixing should be carried out at 14 : 5 : 1 ratio (viral suspension : stabilizing medium, consisting of 40% peptone solution with 8% lactose solution : 4% pectin solution, correspondingly), a semifinished product obtained after mixing should be applied onto a bait (a porous briquette) to be frozen and freeze dried for 24-30 h. The method includes decreased number of stages for manufacturing necessary vaccine being more efficient and economical. The vaccine keeps immunogenic properties for 5 d, not less at environmental temperature being up to 20 C and during storage period for 6 mo at 6-8 C.

EFFECT: higher efficiency of manufacturing.

2 ex, 1 tbl

FIELD: veterinary virology.

SUBSTANCE: invention relates to strain with stable infective and antigen activity useful in controlling of immunogenic activity against infective feline peritonitis, as well as in producing of hyperimmune serums and globulins for diagnosis of said disease.

EFFECT: strain with stable infective and antigen activity.

4 ex

FIELD: biotechnology.

SUBSTANCE: claimed method includes conjugation of capsule polysaccharides A and C with synthesized peptide outer membrane protein fragments of meningococcus of serogroup B, having frank protective activity against to meningococcus serogroups A, B and C. capsule polysaccharides of meningococcus serogroups A and C are used in preparation of bivalent vaccine B/A and B/C, respectively. Said polysaccharide are oxidized before conjugation.

EFFECT: vaccine with improver protective activity against to meningococcus infection of various serogroups.

3 cl, 1 tbl, 7 dwg

FIELD: veterinary science, veterinary surgery.

SUBSTANCE: one should perform wound washing with an antiseptic followed by applying Vilnevski's ointment upon wound's surface and introducing a certain antibiotic, moreover, animals should be subcutaneously injected with antihistamine serum (AHS) at the dosage of 4.0-5.0 ml I combination with ascorbic acid intramuscularly at the dosage of 1.0-1.5 ml once daily, thrice at 5-7-d-long interval, at the background of daily intake of lymphosan at the dosage of 2.0-2.5 g for 8-10 d simultaneously with the fodder applied.

EFFECT: higher efficiency of therapy.

1 ex, 1 tbl

FIELD: veterinary science.

SUBSTANCE: the suggested methods and compositions provide transfer of biologically active compound, antigen predominantly, in animal body. Efficient quantity of biologically active compound should be put into microcapsules made of biocompatible material the size of which do not exceed 10 mcm, then one should introduce efficient quantity of these microcapsules, perorally, preferably, for animals under immunization. As material for microcapsules one usually applies a biologically active polymer or copolymer being of capacity to pass through gastro-intestinal tract or being localized at mucosal surface not being affected by biodegradation. This provides the transfer of biologically active compound onto Peyer's patches or other mucosa-associated lymphatic tissues, that provides inducing systemic immunity and activization of mucosal immunity system.

EFFECT: higher efficiency.

22 cl, 12 ex, 19 tbl

FIELD: medicine and immunology, in particular treatment and prevention immunodeficiency conditions and diseases associated with bacterial or viral aggression.

SUBSTANCE: claimed method includes administration to a patient immunoglobulin drug (e.g., pharmaceutical composition containing 6-12 % of specific heterologous secreted immunoglobulin A, isolated from milk or foremilk of immunized ungulates). Administration is performed parenterally wherein single dose is at least 10 IU/kg of patient weight for treatment or at least 5 IU/kg for prophylaxis; or perorally in dose of 0.2-0.5 g and/or topically one-two times per day for 1-5 days. Method of present invention makes it possible to decrease dose of administrating immunoglobulin due to prolonged retention of its high titers in body fluids.

EFFECT: enlarged range of application and assortment of immunoglobulin drugs.

4 cl, 5 ex

FIELD: microbiology and immunology, in particular immunodiagnosis.

SUBSTANCE: atypical strain of melioidose Burkholderia pseudomallei-111-6-1 with altered phenotype defected with respect to synthesis of 8 antigen and acting as immunosuppressor is used as antigen for animal immunization. Immune serum is obtained after 2 immunization cycles of animal-producer with titer in gel immunodiffusion reaction not less than 1:128.

EFFECT: immune serum with increased specific activity.

2 tbl, 2 ex

FIELD: immunology.

SUBSTANCE: the innovation deals with new immunogenic conjugates of beta-propionamide-bound polysaccharide and N-propionamide-bound oligosaccharide with protein, and the method to obtain these conjugates has been suggested, as well. Conjugates should be applied to obtain vaccines against infectious diseases and cancer that enables to broaden the number of preparations applied in treating the above-mentioned diseases.

EFFECT: higher efficiency.

1 dwg, 2 ex, 8 tbl

FIELD: immunology.

SUBSTANCE: the innovation deals with new immunogenic conjugates of beta-propionamide-bound polysaccharide and N-propionamide-bound oligosaccharide with protein, and the method to obtain these conjugates has been suggested, as well. Conjugates should be applied to obtain vaccines against infectious diseases and cancer that enables to broaden the number of preparations applied in treating the above-mentioned diseases.

EFFECT: higher efficiency.

1 dwg, 2 ex, 8 tbl

FIELD: medicine, juvenile surgery.

SUBSTANCE: the method is characterized by the fact that 3 wk before surgical dissection of adhesions due to laparoscopy one should prescribe bifiform per 1 capsule and Hilak-Forte per 10-15 drops thrice daily. Moreover, 7 d before surgical interference it is necessary to conduct 7 seances of electrophoresis with irucsol and prescribe smekta sorbent per 1 packet thrice daily. Then comes laparoscopic dissection of adhesions, and after surgical interference one should perform electrophoresis with irucsol for 7 d. After appearance of intestinal peristaltics it is necessary to apply smekta per 1 packet thrice daily for 7 d. Since the 8th after operation one should prescribe bifiform per 1 capsule and Hilak-Forte per 10-15 drops thrice daily for 1 mo. Then 1 mo after laparoscopy one should prescribe electrophoresis with collalysine up to 8-10 procedures at simultaneous abdominal massage and curative-physical culture complex for 8-10 d. The method enables to obtain antiadhesive effect in 92% cases of surgical dissection of adhesions due to complex impact upon pathogenesis of adhesive disease, at decreased number of relapses.

EFFECT: higher efficiency of therapy.

2 ex

Up!